Clinical Trials Logo

Treatment clinical trials

View clinical trials related to Treatment.

Filter by:

NCT ID: NCT05441761 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

Start date: May 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy mitoxantrone hydrochloride liposome in combination with gemcitabine, dexamethasone, and cisplatin in relapsed/refractory peripheral T-cell lymphoma

NCT ID: NCT05434130 Recruiting - Inflammation Clinical Trials

Modulating Exercise Dosage to Improve Concussion Recovery

MEDIC
Start date: August 5, 2022
Phase: Phase 2
Study type: Interventional

Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 14 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae. Findings from this research will lead to more rigorous and precise rehabilitation guidelines and improved understanding about how exercise affects neurophysiological function among adolescents with concussion.

NCT ID: NCT05430867 Not yet recruiting - Alzheimer Disease Clinical Trials

Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Memantine is recommended for the treatment of moderate and severe AD patients. Sodium oligomannate (GV-971) is a marine-derived oligosaccharide. It is proposed that it can reconstitute the gut microbiota, and inhibit neuroinflammation in the brain as observed in animal models. It reduces Aβ deposition in the brain of Aβ-transgenic mice. The reduction in both Aβ deposition and neuroinflammation may synergistically contribute to the improvement of cognitive impairment and delay the progress of the disease. China Food and Drug Administration(CFDA)approved it for the treatment of mild to moderate AD in 2019. Due to the different mechanism of memantine and GV-971, theoretically, they may synergistically improve cognitive function and delay disease progression. However, there is a lack of data on their effectiveness and safety. Therefore, the purpose of this study is to compare the efficacy and safety of memantine and GV-971 monotherapy and combination therapy in patients with moderate to severe AD, which is of great significance for guiding the treatment of moderate and severe AD.

NCT ID: NCT05347537 Completed - Pain Clinical Trials

Effects of Mulligan's Mobilization With and Without Clamshell Exercises in Sacroiliac Joint Dysfunction

Start date: April 27, 2022
Phase: N/A
Study type: Interventional

Sacroiliac joint dysfunction is the changing of joint structure (ligaments, muscles and cartilage) that cause impairments and movement restrictions. It is one of the primary sources of low back pain among female population and often misdiagnosed. Almost 15-30% patients are suffering from sacroiliac joint dysfunction who presented with the complaint of low back pain. The aim of the study is to determine the effect of mulligan's mobilization with and without clamshell exercise on pain, disability and quality of life in patients with sacroiliac joint dysfunction.

NCT ID: NCT05345600 Recruiting - Pain Clinical Trials

MILTA vs Placebo Use Comparison for the Management of Pain Related to Perineal Scars Following Delivery

MILTADoIP
Start date: March 15, 2022
Phase: N/A
Study type: Interventional

The incidence of perineal scars after a pregnancy is high, either related to an episiotomy or to spontaneous perineal tears. These perineal scars can result in acute pain but also in chronic pain for some women. Medical treatment includes level 1 and 2 analgesics and, even for a few women, level 3 analgesic. The MILTA® uses photons which are emitted with low intensity in the visible and near infrared combining 5 physical principles to reduce pain : 1- The NPCL (Nano-Pulsed Cold Laser) emissions in coherent infrared light, at 905 nanometers; 2- Non-coherent emissions, pulsed by trichromatic RGB CSM diodes (400 to 650 nm); 3- Continuous non-coherent infrared emission monochromatic diodes at 905 nm; 4- A constant circular magnetic field (200 millitesla) equivalent to the terrestrial magnetic field and 5- The effect of magnetic tunnel which potentiates the light propagation. MILTA® treatment has been shown to be effective in various managements of pain, but has never been used in pain related to perineal scars. This randomized controlled trial aims at assessing MILTA vs placebo to reduce pain related to perineal scars after pregnancy.

NCT ID: NCT05337410 Recruiting - Treatment Clinical Trials

Youth Empowerment Solutions: Engaging Youth for Anti Racism and Cultural Equity

YES-ERACE
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of YES-ERACE (Youth Empowerment Solutions for Engaging Youth for Anti-Racism and Cultural Equity) compared to regular after school programming in increasing youth empowerment, promoting anti-racist behaviors, and decreasing youth violence. Through the evidence-based YES (Youth Empowerment Solutions) program, youth design and implement projects to help improve their communities. In the current study, investigators adapted the existing YES curriculum to empower youth from diverse backgrounds to address racism and racial discrimination to reduce violent behavior, including race-based victimization. The adapted curriculum, YES-ERACE, focus on middle school students. The investigators test the effects of YES-ERACE using a group-randomized trial in after-school programs across 6 middle schools, examining the effects of the curriculum on youths' sense of empowerment, racism attitudes, and violent behavior. Dose-response and sustainability of YES-ERACE effects are also examined.

NCT ID: NCT05291195 Completed - Treatment Clinical Trials

Treatment of Young Permanent Teeth With Different Adjuvant Approaches

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

To determine microbiology assessment of infected root canal in young permanent teeth, as well as antimicrobial efficiency of different adjuvant treatment modalities including photodynamic therapy (PDT), high-power diode laser, and essential oils following mechanic-chemical treatment in the treatment of periapical periodontitis in these teeth.

NCT ID: NCT05285332 Not yet recruiting - Breast Neoplasms Clinical Trials

Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy

CS
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

For patients with de novo stage IV breast cancer, the current debate is whether local surgery can improve the survival of patients. There is no clinical study on the classification after systemic treatment of de novo stage IV breast cancer patients. In fact, the clinical stage of tumor can change with the change of treatment. For example, the stage Ⅲ of locally advanced breast cancer can down-staging to the stage Ⅱ after systemic treatment. Similarly, patients with stage Ⅳ can down-staging to stage Ⅱ or stage Ⅲ after systemic treatment. At this time, the patient can receive surgical treatment. Therefore, this study is to first treat de novo stage IV breast cancer patients with systemic treatment, according to the response after systemic treatment to give different treatment measures(surgery or continued systemic treatment). The investigators hope that this study will provide new ideas for the treatment of de novo stage IV breast cancer and other de novo stage IV cancers.

NCT ID: NCT05279157 Completed - Keratoconus Clinical Trials

Autologous Adipose-Derived Adult Stem Cell Implantation for Corneal Diseases (ADASCs-CT-CD)

ADASCs-CT-CD
Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

Cellular therapy of the corneal stroma with implantation of mesenchymal stem cells derived from autologous adipose tissue with or without a carrier (scaffold) composed by decellularized human donor corneal stroma is used in patients with corneal diseases such as corneal dystrophies, and keratoconus. For this purpose, the study planned to assess the enhancement of visual acuity, pachymetric, and aberrometric parameters with implantation of autologous mesenchymal adipose tissue-derived adult stem cells (ADASCs) alone, 120 µm thickness of decellularized or recellularized laminas with ADASCs. Three groups will be included in the study: (1) Implantation of a single dose of ADASCs alone without scaffold. (2) Implantation of decellularized human corneal lamina without ADASCs. (3) Implantation of the recellularized human corneal lamina with ADASCs.

NCT ID: NCT05243134 Recruiting - Treatment Clinical Trials

The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation

Start date: September 30, 2021
Phase:
Study type: Observational [Patient Registry]

All the data of patients with patellar dislocation will be collected to evaluate the anatomic deformities. The data includes X-ray, CT, MRI examinations, medical records, and physical examination information. Finally, we correlate the anatomic deformities with clinical efficacy. To search for the risk factors that lead to patellar dislocation and influence the therapeutic effect.